Evidence map›Paper›PMID 42243790›Full record

ArticleJournal of nanobiotechnology2026

Targeting the HIF-1α/PPARγ axis with curcumin carbon dots to combat uranium nephrotoxicity.

Zhimin Jia, Chang Wang, Xiaowen Han, Jiawei Zeng, Chuandong He, Zhengguo Chen, Yan Chen, Bei Xu

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhimin JiaDepartment of Nuclear Medicine, NHC Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, 621000, China.
Chang WangDepartment of Clinical Laboratory, Jiangyou 903 Hospital, Mianyang, 621000, China.
Xiaowen HanDepartment of Nuclear Medicine, NHC Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, 621000, China.
Jiawei ZengDepartment of Clinical Laboratory, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, 621000, China.
Chuandong HeDepartment of Nuclear Medicine, NHC Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, 621000, China.
Zhengguo ChenDepartment of Nuclear Medicine, NHC Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, 621000, China. maiwang342@163.com.
Yan ChenDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, 610000, China. cyfy1112@163.com.
Bei XuDepartment of Nuclear Medicine, NHC Key Laboratory of Nuclear Technology Medical Transformation, Sichuan Provincial Engineering Research Center of Nuclear Medical Equipment Translation and Application, Sichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang, 621000, China. xb1990625@126.com.

Funding

Health Commission of Sichuan Province Medical Science and Technology Program 24QNMP035Health Commission of Sichuan Province Medical Science and Technology Program 25QNMP055Incubation Project of Mianyang Central Hospital 2024FH002Incubation Project of Mianyang Central Hospital 2025FH002NHC Key Laboratory of Nuclear Technology Medical Transformation (MIANYANG CENTRAL HOSPITAL) 2022HYX007NHC Key Laboratory of Nuclear Technology Medical Transformation (MIANYANG CENTRAL HOSPITAL) 2024HYX021Sichuan Medical Association Youth Innovation Project Q20250002Sichuan Province Medical Research Project Program S23067Traditional Chinese Medicine Research Program of Sichuan Administration of Traditional Chinese Medicine 2024MS584
6 · The paper itself

Abstract

Uranium-induced nephrotoxicity involves complex mechanisms and lacks therapeutic interventions. This study identifies the HIF-1α/PPARγ axis as a key driver of renal lipid reprogramming and injury following uranium exposure. Using molecular docking, co-immunoprecipitation (Co-IP), ChIP-qPCR, and dual-luciferase reporter assays, we confirmed that HIF-1α directly regulates PPARγ expression and downstream lipotoxicity. The causal role of this axis was further validated using HIF-1α knockdown/knockout models and PPARγ pharmacological modulators (GW9662 and Rosi). Curcumin-derived carbon dots (CCDs) were synthesized at temperatures ranging from 120 to 210 °C. As-prepared CCDs-210 exhibited uniform size (< 10 nm), and excellent biocompatibility. Carbonization temperature governed cellular uptake: CCDs-210 entered via active endocytosis, while CCDs-120 used passive diffusion. In uranium-exposed HK-2 cells, CCDs-210 scavenged ROS, stabilized mitochondrial membrane potential, and suppressed the HIF-1α/PPARγ axis, reversing lipid dysregulation and improving cell viability. In vivo, CCDs-210 attenuated renal histopathological damage, restored renal function, and conferred multi-organ protection. These findings establish the HIF-1α/PPARγ axis as a central mediator of uranium nephrotoxicity and demonstrate that CCDs-210, by targeting this axis, effectively mitigate oxidative stress, inflammation, and lipid metabolic disruption. This work provides both a mechanistic foundation and a translatable nanotherapeutic strategy for treating uranium-induced kidney injury.

Indexed as

CurcuminHypoxia-Inducible Factor 1, alpha SubunitPPAR gammaUraniumAnimalsCarbonCarbon Quantum DotsCell LineCell SurvivalHumansKidneyMaleMiceReactive Oxygen SpeciesCarbonCurcuminHypoxia-Inducible Factor 1, alpha SubunitPPAR gammaReactive Oxygen SpeciesUraniumCurcumin-derived carbon dotsHIF-1α/PPARγ axisKidney injuryLipid ReprogrammingUranium

Identifiers

PMID42243790
PMCPMC13450521

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.